ストックスクリーナーアプリを入手
987.05
0.18%
-1.82
アフターアワーズ：
984.50
-2.55
-0.26%
前日終値:
$988.87
開ける：
$991.35
24時間の取引高:
3.74M
Relative Volume:
1.15
時価総額：
$880.19B
収益：
$72.25B
当期純損益:
$25.28B
株価収益率:
35.53
EPS:
27.781
ネットキャッシュフロー:
$10.37B
1週間 パフォーマンス:
+15.96%
1か月 パフォーマンス:
+6.47%
6か月 パフォーマンス:
+5.29%
1年 パフォーマンス:
+27.34%
1日の値動き範囲:
$983.50
$996.49
1週間の範囲:
$896.80
$996.49
52週間の値動き範囲:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Compare LLY vs JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
987.05 | 881.82B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
224.62 | 542.95B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
205.03 | 364.56B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
184.92 | 281.08B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
148.36 | 277.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-16 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 繰り返されました | BofA Securities | Buy |
| 2025-12-15 | 繰り返されました | Goldman | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-10 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 繰り返されました | BMO Capital Markets | Outperform |
| 2025-10-14 | アップグレード | Erste Group | Hold → Buy |
| 2025-09-17 | ダウングレード | Berenberg | Buy → Hold |
| 2025-08-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2025-08-18 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | ダウングレード | Erste Group | Buy → Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-09-13 | 再開されました | Citigroup | Buy |
| 2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
| 2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
| 2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-20 | 再開されました | UBS | Buy |
| 2023-08-09 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-26 | 繰り返されました | Citigroup | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | UBS | Buy |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-09-22 | アップグレード | UBS | Neutral → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-03-10 | 開始されました | Daiwa Securities | Outperform |
| 2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-16 | 繰り返されました | BofA Securities | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-21 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
| 2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-03-12 | 開始されました | JP Morgan | Overweight |
| 2019-01-23 | 開始されました | UBS | Buy |
| 2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-10-01 | 繰り返されました | SunTrust | Buy |
| 2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
Lilly looks to sell about $8B of debt to fund acquisitions - Indianapolis Business Journal
Quarterly Sales Reach $8.7 Billion, Eli Lilly’s Mounjaro Becomes New Blockbuster Drug King - NAI500
Eli Lilly's Mounjaro overtakes Merck's Keytruda as world's top-selling drug - Business Standard
Change of leadership in the pharmaceutical world! Eli Lilly and Co's Mounjaro surpasses Merck & Co's Keytruda to become the world's best-selling drug. - 富途牛牛
Change of the top-selling drug! Eli Lilly and Co's Mounjaro surpasses Merck & Co's Keytruda to become the world's best-selling drug. - 富途牛牛
Lilly unveils new genetic medicine facility in Lebanon LEAP District and $4.5 billion investment - WFYI
Lilly’s Mounjaro overtakes Keytruda as world’s top-selling drug - The Boston Globe
Eli Lilly: Files for Eight Part Notes Offerin - Moomoo
Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence - Yahoo Finance
Top Research Reports for Eli Lilly, Western Digital & Vertiv - Yahoo Finance Singapore
[144] ELI LILLY & Co SEC Filing - Stock Titan
Eli Lilly Kicks Off High-Grade Bond Sale in Push to Fund Deals - Bloomberg.com
Lilly’s Mounjaro Overtakes ‘King Keytruda’ as World’s Top-Selling Drug - Bloomberg.com
Meet the minds behind CrossBridge Bio, Eli Lilly's $300M Houston buy - The Business Journals
Eli Lilly Opens First Dedicated Genetic Medicine Facility - Pharmaceutical Commerce
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits? - Yahoo Finance Singapore
Lilly Invests $4.5 Billion to Expand Indiana Manufacturing Sites - Bloomberg.com
Lilly pours $4.5B more into LEAP, as first facility opens in Lebanon - AOL.com
Eli Lilly commits additional $4.5B to Indiana manufacturing sites - WTHR
Lilly to invest additional $4.5 billion across Indiana manufacturing sites - WRTV
Lilly commits additional $4.5 billion in Indiana manufacturing sites - Reuters
Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions - Moomoo
Eli Lilly and Company announces additional $4.5 billion investment in 2 Lebanon sites - fox59.com
Eli Lilly (LLY) Stock: Lilly Is Building the Largest Drug Plant in U.S. History - CoinCentral
Lilly commits $4.5 billion to Indiana manufacturing expansion By Investing.com - Investing.com Canada
Lilly announces additional $4.5B investment at LEAP District manufacturing site - Inside INdiana Business
Lilly invests $4.5 billion to expand Indiana manufacturing sites - MSN
Novo Nordisk weight-loss pill powers profit beat in race to catch Eli Lilly - Reuters
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility - investor.lilly.com
Eli Lilly (LLY) files prospectus for multi‑series floating and fixed notes - Stock Titan
Wegovy Pill Debut 'Fattens' Novo Nordisk's Profit Outlook - Benzinga
Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight - TechStock²
Novo Nordisk’s weight loss pill helps narrow gap with rival Lilly - whbl.com
Signal: Eli Lilly Stock Remains a "Buy" After Earnings - Schaeffer's Investment Research
Foundayo Liver Safety Questions Test Eli Lilly GLP-1 Growth Story - simplywall.st
Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show - 24/7 Wall St.
Are analysts too quick to gloss over Lilly’s liver case? - statnews.com
Eli Lilly Is Maintained at Overweight by Barclays - Moomoo
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,183 to $1,500 - 富途牛牛
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Icon (ICLR) - The Globe and Mail
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years - investor.lilly.com
Eli Lilly Stock (LLY) Opinions on Q1 Earnings and Foundayo Safety Report - Moomoo
3 Reasons It's Not Too Late to Buy Eli Lilly Stock - The Motley Fool
Eli Lilly and Co To Go Ex-Dividend On May 15th, 2026 With 1.73 USD Dividend Per Share - Moomoo
Is Eli Lilly stock heading for $1,000? - MSN
Eli Lilly Annual Meeting: Directors Win, Governance Changes Fail as Ricks Touts 45% Revenue Jump - Yahoo Finance
Is Eli Lilly Stock Heading for $1,000? - The Motley Fool
Eli Lilly (LLY) Faces Share Decline Amid Liver Failure Report Li - GuruFocus
Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125% - 24/7 Wall St.
Eli Lilly Recovers After Weight-Loss Patient Reports A Surprise Side Effect - Investor's Business Daily
Stock Quote & Chart | Eli Lilly and Company - investor.lilly.com
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
2.03%
大文字化:
|
ボリューム (24 時間):